Corona Remedies share price: The opening of the Corona Remedies share price was head-turning at Dalal Street, and understandably so. A bold venture into the secondary market was evident in the fact that the stock made a healthy entry, with no interest turning away as soon as the IPO window was shut.
When you are looking at the share price of Corona Remedies today, the opening contrasted this positive result, and the company has listed at a steep price above its IPO price and immediately captured market interest.
So a question and curiosity raises, what drove this buzz? The solution is the strong demand that the company had received during the public issue process, which flowed well into listing day. Add to that a conducive wider market atmosphere, and you have the ideal ingredients for a good debut. For sideliners, this was no ordinary listing, as it served as a reminder that when fundamentals combine with timing, markets are likely to reward confidence. Whether it is too late to invest or just read between the lines, the opening of Corona Remedies definitely got Dalal Street on alert.
Market Performance: Corona Remedies Share Price Today On NSE and BSE
- Strong NSE debut: Corona Remedies shares opened firmly on the NSE, delivering a solid premium at the opening bell.
- NSE listing price: ₹1,470 per share
- Premium over IPO price (NSE): 38.42%
- BSE listing price: ₹1,452 per share
- Premium over IPO price (BSE): 36.72%
- Post-listing market capitalisation: ₹8,880.44 crore, signaling a confident and well-received entry into the public markets.
Corona Remedies On BSE
- The Corona Remedies share price on the BSE reflected strong investor enthusiasm.
- The stock listed at ₹1,452 per share, delivering a solid premium over its IPO price.
- Pricing on the BSE closely matched the NSE listing, showing consistency across exchanges.
- This parallel performance suggests broad-based investor interest, not exchange-specific trading.
Corona Remedies IPO Snapshot: Key Numbers and Listing Highlights
| Category | Details |
|---|---|
| Issue Size | ₹655.37 crore |
| Price Band | ₹1,008 – ₹1,062 per share |
| Anchor Investment Raised | ₹195 crore |
| Subscription Response | 137.04x overall subscription |
| NSE Listing Premium | Nearly 38% over IPO price |
| BSE Listing Performance | Similar strong premium |
| Market Debut Outlook | Strong listing sets a positive tone |
| Overall Assessment | Firm entry into public markets; one of the session’s notable listings |
Aishwarya is a journalism graduate with over three years of experience thriving in the buzzing corporate media world. She’s got a knack for decoding business news, tracking the twists and turns of the stock market, covering the masala of the entertainment world, and sometimes her stories come with just the right sprinkle of political commentary. She has worked with several organizations, interned at ZEE and gained professional skills at TV9 and News24, And now is learning and writing at NewsX, she’s no stranger to the newsroom hustle. Her storytelling style is fast-paced, creative, and perfectly tailored to connect with both the platform and its audience. Moto: Approaching every story from the reader’s point of view, backing up her insights with solid facts.
Always bold with her opinions, she also never misses the chance to weave in expert voices, keeping things balanced and insightful. In short, Aishwarya brings a fresh, sharp, and fact-driven voice to every story she touches.
